This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F13%3A00057977%21RIV14-MZ0-00023001/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F13%3A00057977%21RIV14-MZ0-00023001
rdf:type
skos:Concept n13:Vysledek
rdfs:seeAlso
http://www.pccj.eu/images/stories/Supplements/PCCJ_Concor_AM_Position_Paper_WEB.pdf
dcterms:description
Despite the availability of effective therapies, there remains poor awareness, diagnosis and management of hypertension across the globe. Effective treatment requires an understanding of the underlying disease processes involved in hypertension which includes chronic increased sympathetic activity and peripheral resistance rather than focusing simply on blood pressure reduction. The differing pathophysiological response patterns of younger and older hypertensive patients require different treatment pathways and combination antihypertensive therapy is increasingly being used to tackle this heterogeneous condition and to meet international targets for blood pressure reduction. The combination of beta-blockers and calcium channel blockers is recommended in international guidelines for the effective management of hypertension. Combination of these two complementary drug classes targets both heart rate and high sympathetic activity, and abnormal peripheral vascular resistance and arterial stiffness. This review provides a rationale for the combination of dihydropyridine calcium channel blockers and beta1-selective beta-blockers, and highlights the value of fixed-dose combinations in managing hypertension. Despite the availability of effective therapies, there remains poor awareness, diagnosis and management of hypertension across the globe. Effective treatment requires an understanding of the underlying disease processes involved in hypertension which includes chronic increased sympathetic activity and peripheral resistance rather than focusing simply on blood pressure reduction. The differing pathophysiological response patterns of younger and older hypertensive patients require different treatment pathways and combination antihypertensive therapy is increasingly being used to tackle this heterogeneous condition and to meet international targets for blood pressure reduction. The combination of beta-blockers and calcium channel blockers is recommended in international guidelines for the effective management of hypertension. Combination of these two complementary drug classes targets both heart rate and high sympathetic activity, and abnormal peripheral vascular resistance and arterial stiffness. This review provides a rationale for the combination of dihydropyridine calcium channel blockers and beta1-selective beta-blockers, and highlights the value of fixed-dose combinations in managing hypertension.
dcterms:title
Current approaches to combination therapy for essential hypertension: the rationale for combined calcium, channel blockade and beta-blockade Current approaches to combination therapy for essential hypertension: the rationale for combined calcium, channel blockade and beta-blockade
skos:prefLabel
Current approaches to combination therapy for essential hypertension: the rationale for combined calcium, channel blockade and beta-blockade Current approaches to combination therapy for essential hypertension: the rationale for combined calcium, channel blockade and beta-blockade
skos:notation
RIV/00023001:_____/13:00057977!RIV14-MZ0-00023001
n13:predkladatel
n14:ico%3A00023001
n3:aktivita
n16:N
n3:aktivity
N
n3:cisloPeriodika
suppl. 2
n3:dodaniDat
n9:2014
n3:domaciTvurceVysledku
n12:6361579
n3:druhVysledku
n11:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n17:predkladatel
n3:idSjednocenehoVysledku
67515
n3:idVysledku
RIV/00023001:_____/13:00057977
n3:jazykVysledku
n7:eng
n3:klicovaSlova
beta-blockade; calcium channel blockade; hypertension
n3:klicoveSlovo
n5:beta-blockade n5:calcium%20channel%20blockade n5:hypertension
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[40FF5B72970A]
n3:nazevZdroje
Primary care cardiovascular Journal
n3:obor
n15:FA
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n9:2013
n3:svazekPeriodika
6
n3:tvurceVysledku
Narkiewicz, Krzysztof Struijker-Boudier, Harry AJ Kancz, Sandor Willenheimer, Ronnie Ruilope, Luis Gotcheva, Nina Bruthans, Jan Cruickshank, John
s:issn
1756-5138
s:numberOfPages
9